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Abstract
Background: FMD is one of the major causes of economic loss of cloven-hoofed animals in the world today. The
assessment of dominant genotype/lineage and prevalent trends and confirmation the presence of infection or
vaccination not only provides scientific basis and first-hand information for appropriate control measure but also
for disease eradication and regaining FMD free status following an outbreak. Although different biological and
serological approaches are still applied to study this disease, ELISA test based on the distinct format, antigen type
and specific antibody reinforce its predominance in different research areas of FMD, and this may replace the
traditional methods in the near future. This review gives comprehensive insight on ELISA currently available for
typing, antigenic analysis, vaccination status differentiation and surveillance vaccine purity and content at all stages
of manufacture in FMDV. Besides, some viewpoint about the recent advances and trends of ELISA reagent for FMD
are described here.
Methods: More than 100 studies regarding ELISA method available for FMD diagnosis, antigenic analysis and
monitor were thoroughly reviewed. We investigated previous sagacious results of these tests on their sensitivity,
specificity.
Results: We found that in all ELISA formats for FMD, antibody-trapping and competitive ELISAs have high
specificity and RT-PCR (oligoprobing) ELISA has extra sensitivity. A panel of monoclonal antibodies to different sites
or monoclonal antibody in combination of antiserum is the most suitable combination of antibodies in ELISA for
FMD. Even though from its beginning, 3ABC is proven to be best performance in many studies, no single NSP can
differentiate infected from vaccinated animals with complete confidence. Meanwhile, recombinant antigens and
peptide derived from FMDV NPs, and NSPs have been developed for use as an alternative to the inactivated virus
antigen for security.
Conclusions: There is a need of target protein, which accurately determines the susceptible animal status based
on the simple, fast and reliable routine laboratory test. A further alternative based on virus-like particle (VLP, also
called empty capsids) in combination of high throughput antibody technique (Phage antibody library/antibody
microarray) may be the powerful ELISA diagnostic reagents in future.
Introduction
Foot and mouth disease(FMD) is a highly contagious
and economically devastating disease of cloven-hoofed
animals which hold a wide of the host spectrum such as
cattle, pigs, sheep, goats, buffalo, deer, antelope and wild
pigs and can severely constrain international trade of
animals and animal products. FMD is caused by FMD
virus (FMDV), a virus in the genus Aphthovirus within
t h ef a m i l yP i c o r n a v i r i d a e[ 1 ] .T h eg e n o m ei so v e r8k b
in length and encode four structural proteins (SPs, VP1,
VP2, VP3 and VP4)that form an icosahedrical capsid
[2], and a total of ten mature non-structural proteins
(NSPs)(L, 2A, 2B, 2C, 3A, 3B, 3C, 3D; or some complex,
such as 3AB or 3ABC). Though the genome of FMDV
is small, it has a high mutation rate and spontaneous. In
FMDV, structural proteins are more variable than non-
structural proteins. Mutations or deletions in structural
proteins may help FMDV to evade an immune response
produced by the host [3]. Furthermore, the variations
are unequally distributed among the four structural pro-
teins, particularly the VP1 protein, which shows the
most frequently variability due to its significant roles in
virus attachment, protective immunity, and serotype
specificity. Antigenically, this virus exists as seven
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any medium, provided the original work is properly cited.distinct serotypes (i.e., O, A, C, Asia 1 and SAT1-3) and
multiple subtypes or antigenic variants within each sero-
type [4,5], which make the vaccine from one serotype
does not confer protection against the other serotype.
Consequently, vaccine strain requirements differ accord-
ing to the type and subtypes of virus prevailing globally
and the antigenic drift or antigenic shift of circulating
virus or field isolates have to be survey on a large scale
and matching vaccines have to be selected with care.
Currently, vaccination remains the most effective coun-
termeasure against FMDV, but, which complicated the
problem of differentiate infected and vaccinated animals.
Confront with parallel infection and vaccination, an
accurate assessment to susceptible animal in a long
range is urgent for determining the following control
measures but also difficult due to lack of effective inves-
tigation approach. These limitations make the search for
stable and safe test become an active area of research.
In this review, the ELISA methodology and its utiliza-
tion in the identification, detection and quantification of
viral particle or viral antigens or specific antibodies are
discussed. The newly reagent and skills, which show
great promise but is still in the early stages of develop-
ment was described as well.
1 ELISA for FMDV diagnosis/typing
Typical Clinical signs of FMD are characterised by a
vesicular condition of the feet, buccal mucosa, rhinar-
ium and the mammary glands of the females. Therefore,
FMD cannot be differentiated clinically from other vesi-
cular diseases, such as vesicular stomatitis, swine vesicu-
lar disease and vesicular exanthema. As a result,
laboratory diagnosis of suspected FMD cases became a
matter of significance.
Although methods based on virus isolation or the
demonstration of FMD viral antigen or nucleic acid in
samples of tissue or fluid or culture products is suffi-
cient for a positive diagnosis, in general, the ELISA [6,7]
using type-specific serological reagents is the preferred
procedure for the detection of FMD viral antigen and
identification of viral serotype in the early stages of
research. Owing to it is more specific, sensitive and effi-
cient, and it is not impacted by pro- or anti-complement
factors [8] the ELISA has access to better development
and even replaced complement fixation (CF) in most
laboratories in the early research phase of FMD. Con-
t r a s tt oC Fa n dv i r u si s o l a t i o n ,a l m o s tt h ee q u i v a l e n t ,
even the higher of sensitivity was achieved in ELISA
[9-11]. Different ELISA formats, particularly belonging
to indirect ELISA, involved in blocking- or competition-
or sandwich-based assays have been playing an increas-
ing important role in the identification of FMDV sero-
type. The most common practice in the early period of
the examination of FMD is that serotype-specific
polyclonal antibodies (PAbs) or antiserum [7] to 146S
( i n t a c tF M Dv i r i o n )a n t i g e no fs i n g l eo re a c ho ft h e
seven serotypes of FMDV from rabbit and guinea-pig
are used as trapping antibody and detecting antibody to
develop a double-antibody sandwich ELISA (DAS-
ELISA). In addition, the utilization of pre-coated micro-
plate and freeze-dried reagents greatly extended those
assays’ applications field and shelf time [12]. However,
there is experimental evidence that the similar level of
neutralizing antibody against the first FMDV was stimu-
lated by the heterotypic 146S particles and homotypic
146S particles. This displayed a similarity in the anti-
genic structure among the different serotypes and might
sharply reduce the sensitivity of ELISA, which antibodies
to 146S were adopted in. Practically, 12S particles, pro-
duced by mild acid treatment disruption of the 146S
particle or by heating at 56°C, appear to be as active as
146S in inducing neutralizing antibody in guinea-pig
inoculated with 146S particles [13-16], though there is a
low neutralizing activity. Considering as a part of the
146S antigenic site, the 12S particles become a fresh
substitute antigen for intact virus in serum preparation
[11]. Further, an examination based on 12S particles was
exploited as well [10]. However, a little deficiency
existed in the abovementioned procedure is that the
samples need to be treated to obtain subunits prior test.
Antisera is important for many purposes, but they have
some proportion of false-positive reactions or unex-
pected cross-reactivity owing to complex components.
Moreover, the drawback related to limited production
and heterogeneity lead to be difficult to standardization
and hinder a large-scale application of antisera. As an
alternative to guinea-pig or rabbit antisera, appropriate
monoclonal antibodies (MAbs) secreted by specific
hybridoma cells are considered the most promising of
diagnostic reagents in terms of homogeneity and specifi-
city and itself and peroxidase-conjugated can be used as
capture antibody and detecting antibody, respectively.
A serotype-specific Mab-based antigen detection
ELISA in use at the Istituto Zooprofilatico Sperimentale,
Brescia, Italy [17], relies on a mixture of at least 3 differ-
ent Mabs against each of the serotypes O, A and C to
detect FMD virus in clinical samples. And complex-
trapping-blocking [18] ELISAs using combinations of
serotype-specific Mabs have been developed as well.
Furthermore, numerous assays were built on the base of
combination of PAbs and MAbs or two-MAbs system
[19]. But it is worth pointing out that, in most cases,
polyclonal antibodies are a better choice as coating anti-
gen in former system and pairs of monoclonal antibo-
dies subjecting to different antigen sites is necessary for
the latter. In order to further enhance sensitivity, an
approach of trace detection known as RT-PCR (oligo-
probing) ELISA [20,21] in both solid and/or aqueous
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bright prospect in mild subclinical infection or persis-
tently infected carriers of lacking specific symptoms.
Due to the highly contagious nature of FMD, the labora-
tory diagnosis related to live virus must be done in a
laboratory that corresponds with the OIE requirements
for Containment Group 4 pathogens. For the purpose of
reducing the disease security risk involved compared
with the use of live virus, inactivated antigens or tryp-
sin-treated virus or proteins isolated by chemical or
enzymic treatment of intact FMDV or recombinant pro-
teins, particularly, the expressed VP1 protein [22] was
proven to be a more accurate, safe target to examine
FMDV and minimize the occurrence of false-positive
results.
Currently, there is a little FMDV antigen detection
test that employs the use of serotype-independent cross-
reactive reagents. To aid improved diagnosis, Muller et
al. [23] developed an assay system of serotype-indepen-
dent FMDV antigen detection of all seven serotypes of
FMDV using newly developed chickens antiserum tar-
g e t i n gah i g h l yc o n s e r v e dr e g i o nl o c a t e dw i t h i nt h e
structural protein 1AB (accordingly named 1AB’) [24]
and a recently identified cross-serotype reactive mono-
clonal antibody recognized the N terminal of 1B [25].
2 ELISA for antigenic profile and epitopes analysis of
FMDV
Owing the characteristics of quasispecies, natural isolate
FMD viruses derived from different outbreaks showed
much antigenic difference, which generally results in
vaccine lacking effective protection against those FMD
epidemic strains and even causing FMD outbreak. It is,
therefore, an essential part of the epidemiological survey
to assess regularly the antigenic characteristics of field
isolates. Continuous monitoring of the antigenic rela-
tionship of field isolates in relation to the reference vac-
cine strain will provide an up to date knowledge about
the efficacy of the vaccine virus in use and also has
access to select the most suitable vaccine strains in case
of emergency vaccination. Antigenic profiling by ELISA
using panels of well-characterised MAbs [26] is suitable
approaches for selecting representative virus isolates for
vaccine matching. ELISA also has been used as a rapid
method for assessing the relationship of vaccine virus
strains with field virus strains collected [27] or those
from outbreaks and subsequently, the liquid phase
blocking (LPB) ELISA has been in use as an alternative
to serum neutralization test (SNT) in determining the
protective antibody response [28,29] and assessing the
antigenic relationship of field viruses [30,31]. The result
obtained in ELISA test was more appropriate towards
incorporation of O1/Manisa into the vaccination pro-
gram [31]. And the use of multiple Mabs has the
advantage that it is less likely that a field virus will fail
to possess at least one of the epitopes recognised by the
antibodies. Antibodies that neutralize viral infectivity
provide an important mechanism of protection against
FMD. Thus, it is important to define epitopes, especially
those ones that elicit the protective immune response
and their variation or conservation among variants, sub-
types and serotypes. In addition, the analysis of epitopes
profile may provide significant reference for studying in
aspects of molecular recognition, molecular immunol-
ogy, particularly in the field of the selection of appropri-
ate candidate vaccine strains. Traditional methods for
defining linear antigenic epitopes, especially those neu-
tralizing antigenic sites in more detail, include cloning
and sequencing escape mutants [32], fragmentation of
proteins either by chemical cleavage or by enzymatic
digestion [33], peptide scanned technology based on
peptide array or synthesizing a large number of peptides
or a set of overlapping peptides corresponding to the
known amino acid sequence of a protein [34,35].
Though some antigenic sites in FMD viruses of sero-
types O, A and C and other Picornaviruses have identi-
fied mainly by abovementioned methods, ELISA- based
approach identifying antigenic sites was still developed
quickly. In 1985, McCullough et al. [36] firstly reported
the usage of the liquid phase ELISA (LP-ELISA) in the
FMDV epitope identification. Following, ELISA using
single or an overlapping set of peptides has been used
to map epitopes on VP1, VP2, VP3, VP4 [37-41].
Recently, another approach to map FMDV-NSP infec-
tion-related B-cell epitopes and T-cell epitopes by ana-
lyzing overlapping peptides which were used in ELISAs
as synthetic peptides [32,42-44] was described.
Since monoclonal antibodies define a specific region, a
large number of viruses can be analyzed against a panel
of Mab in a single test [45]. Such studies [46-50] pro-
v i d ear a p i dm e a s u r eo ft h ee p itope profiles of viruses,
because non-reactivity of a particular Mab is indicative
of a minor antigenic difference between strains [51].
Nevertheless, a competition ELISA-based approach has
been used successfully to define the epitopes of FMDV
[47,52,53]. For confirmatory purposes, refinements to
this approach such as the use of Fab fragments of anti-
bodies or profiling using site-specific mutant viruses
should be considered. Furthermore, to estimate the rela-
tive proportion of anti-FMDV antibodies with different
antigenic site specificities presenting in the antiserum
from cattle, swine and sheep, conventionally immunized
with O1 serotype vaccine, Aggarwal et al. [54] has used
a capture competition ELISA in his work. As described
for a non-serotype specific antigen detection ELISA, the
identification of an epitope shared between all of the
seven serotypes of FMD virus could be the basis of a
non-serotype specific competition ELISA able to detect
Ma et al. Virology Journal 2011, 8:419
http://www.virologyj.com/content/8/1/419
Page 3 of 9antibody to any strain of FMD virus. Due to their highly
conserved nature, epitopes on the NSP’s of the virus are
the most likely candidates for such a site.
3 ELISA for differentiating infected from vaccinated
animals (DIVA)
Control of FMD mainly encompasses vaccination and
slaughter policy, particularly for the FMD-free countries,
and slaughter policy is considered a fundamental mea-
sure. However, some restrictions from economic situa-
tion, social culture, geographical and natural
environment limit this policy to be applied in a large-
scale range in the endemic areas. Consequently, vaccina-
tion or the combination policy of vaccination and
slaughter remain the most effective countermeasure
against FMDV. Though different type of vaccine com-
prising subunit vaccine, peptide vaccine, DNA vaccine
are developed, FMD inactivated vaccine still play a key
role in control campaigns and eradication of FMD [55]
in the majority FMD epidemic countries and territories
because of perfect protection potency. However, another
new problem arises from inactivated vaccine of FMD is
that it is difficult to distinguish vaccinated from infected
animals. And then, A range of ELISA techniques are
currently being evaluated with the intention of produ-
cing ELISAs for routine diagnostic use which are cap-
able of detecting antibody to FMD virus NSP’s. These
methods were described as following:
3D Protein 3D, also known as the virus infection asso-
ciated antigen (VIAA) since antibodies to this antigen
would be detected in serum from recovery animals [56],
is the core subunit of the virus-encoded RNA-dependent
RNA polymerase [57] and responsible for proteolytic
cleavage and viral replication [58].
The antigenicity of 3D protein is highly conserved
among all serotypes [59], holding out the possibility of a
single serological test capable of detecting infection with
any of the seven serotypes of the virus. 3D polymerase
is the first NSP to be used to distinguish FMDV infected
from vaccinated animals. The traditional VIAA is a
semi-purified antigen prepared from the virus grown in
tissue culture. When it is used in ELISA, there are pro-
blems of inadequate reproducibility appearing to be an
inherent characteristic of the semi-purified nature of the
VIAA preparations (World Reference Laboratory,
unpublished findings). In order to address these pro-
blems, recombinant VIAA antigen has considerable
attractions. When used in a simple indirect ELISA,
recombinant 3D can differentiate infected from naive
cattle [60]. The sensitivity of the test is only slightly
lower than the conventional liquid phase blocking
ELISA of Hamblin et al. [61] and the specificity is
approximately 95%. Moreover, the 3D antibody tests can
be used to monitor viral activity in large cattle
populations and for certification of FMDV free animals
for import and/or export testing [59]. Whereas the fol-
lowing research showed that repeatedly vaccinated ani-
mals can develop antibodies to 3D, which demonstrate
3D is insufficient to differentiate infection from
vaccination.
3B Protein 3B, also known as VPg, is the viral gen-
ome-bound protein. It exists in three nonidentical
copies and covalently bound to the 5’ end of the gen-
ome and serves as a primer for virus genome replication
[62]. Besides, the VPg copy number also has a substan-
tial association with the host range and virulence [63].
An epitope-blocking ELISA (EB-ELISA) exploring com-
bination of MAb to 3B core repeat motif (QKPLK) and
purified recombinant 3AB protein was developed by
Oem et al. [64] to evaluate FMD-free herds and vacci-
nated cattle, pigs, goats, and sheep in 2007.
3ABC The polypeptide 3ABC, playing an important
role during the different stages of viral replication
[65-67], is perceived by the most researchers as the
most appropriate antigen to distinguish infection from
vaccination because of its high immunogenicity and
relatively low concentration in FMDV-infected cell
lysates. Numerous different mode of 3ABC-ELISAs
based on the E.coli expression system were developed to
discriminate naïve, infected, vaccinated pig/cattle/sheep
and detect silent infections/subclinical cases, or survey
field samples in FMD-vaccinated or infected populations
[68-71]. In order to imitate native protein as far as pos-
sible, the NSPs expressed in baculovirus expression sys-
tems [58,72,73] was searched. In 2003, Kweon et al. [74]
established Mab linked indirect-trapping ELISA using
the baculovirus expressed 3ABC (mainly amino acid
1417-1835) and MAb against 3A. The equal sensitivity
and specificity were acquired in comparing with com-
mercial kits (baculovirus expressed 3ABC I-ELISA from
USDA and Mab (3A) linked E. coli expressed 3ABC I-
ELISA from IZSLE) during retrospective sero-surveil-
lance. Then, Sørensen et al. [75] modified the method of
Kweon et al. and removed non-specific reactions in sera
of cattle and sheep by filtration and inactivation. Due to
the antigen capture strategy can sharply simplify the
purification step of recombinant protein, Clavijo et al.
[76] established a biotinylated 3ABC competitive ELISA
(cELISA), which demonstrated no differences between
species (cattle, sheep, pigs) and virus serotypes. Other
indirect and competitive ELISAs detecting antibodies to
3ABC have been shown to have equivalent diagnostic
performance characteristic [77,78].
However, the NSPs expressed in E. coli and baculo-
virus expression systems may sometimes create pro-
blems in the interpretation of the results on account of
non-specific reactions. Furthermore, the number of epi-
topes found on such a long recombinant protein may
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[43,79,80]. Moreover, chemically synthesized synthetic
peptides of NSPs were used for DIVA [43,80-82]. Subse-
quently, Foord et al. [83] provided a C-ELISA format on
the basis of complete bacterial expression systems in
2007. The combination of recombinant antibody single
chain variable fragments (scFv) from phage display
libraries with E.coli-derived recombinant 3ABC reflected
the best performance in detecting sera from cattle,
sheep and pigs representing naïve, FMDV-vaccinated or
FMDV-infected animals. The biggest advantage of this
test is safe, economical and without the need for infec-
tious virus, the use of laboratory animals or the costly
maintenance of viable hybridoma cell lines. The results
indicated that scFv displayed the potential to replace
polyclonal or monoclonal antibodies in such assays.
Other NSPs or NPs ELISAs based on other NSPs and
NPs or assays using infection-specific epitopes of NSPs
to remove cross reactivity are being explored [43,80,81].
Moreover, chimeric proteins that infection related B-cell
epitopes of FMDV NSPs, which self-assembled into chi-
meric tymovirus-like particles(TVLPs), was selected as a
candidate antigen for use in I-ELISA for DIVA of differ-
ent species from the field [84]. The function of the non-
structural proteins 2B is not very clear, although it has
hydrophobic domains [85,86]. However, a 2B peptide
ELISA, described by Inoue et al. [42], using a chemically
synthesized 2B peptide (RSTPEDLERAEKQ) as antigen
showed more competitive strength than other NSP tests
in the detection of the early period of infection because
of the characteristic of earlier induction (as early as 1-2
weeks after infection) and longer persistence of the anti-
body to 2B. Then, Ko et al. [87] reported rP13C ELISA
in 2009, which explored the recombinant protein
(rP13C) expressed in insect cells as a diagnostic antigen.
The higher endpoint titers than LPB-ELISA and virus
neutralization test (VNT) was represented in the mea-
sure of sera from goats challenged with FMDV post-
vaccination.
4 ELISA for quantification of FMDV
Usually, the effectiveness or immunogenicity of the vac-
cine depends to a large extent on the content of 146S
and the stability of these particles after virus inactivation
procedures and formulation into vaccines. In the past,
the most common method for the quantification of the
FMD whole virus particle is either CsCl, or linear
sucrose density centrifugation procedure [88], both of
which are labor intensive, time-consuming, require
expensive equipment and cannot assess whether the
virus has been affected by proteolytic enzymes. In recent
years, as a rapid, effective serological method, ELISA,
which not only sharply simplified the detection process,
but also greatly increased sensitivity and specialty, is
emerging crucial and novel application in terms of eva-
luation the amount of intact virus in vaccine. Moreover,
ELISA can simultaneously quantify 146S in many sam-
ples and monitor whole virus particle in each step of
vaccine manufacture as well as being used to test the
effects of medium modification and different culture
models. Since whole particles and subunits share most
of the common epitopes, polyclonal sera against purified
146S particles cross react with subunits. In order to
overcome above cross-reactivity, one strategy for the
specific detection of 146S based on pairs and single
MAb, which bound only to 146S and not to the subunit
particle was demonstrated by Van Manaan et al. [89]
and Crowther et al. [90] in the presence of virus subu-
nits (12S), respectively. Then, during in-process controls,
Alonso et al. [91] quantified antigen mass adopting the
panels of MAb to FMD types O, A and C in an indirect
sandwich ELISA (IS-ELISA). In 2008, Yang et al. [92]
further optimized the method of Van Manaan et al. by
employing polyclonal antibodies as the capture antibody
and promoted the quantification of 146S of FMDV sero-
type O and A to nanogram level. In 2010, Capozzo et al.
[93] firstly developed an in-process control filtration-
assisted chemiluminometric immunoassay to quantify
FMDV non-capsid proteins in vaccine-antigen batches.
A detection limit, 2 ng for purified NCP and 4 ng for
vaccine-antigen batches spiked with NCP, was gained in
this method.
Conclusion
FMD, which is an acute, contagious disease of cloven-
hoofed animals, has caused huge economic losses since
the finding and is still prevalent in many parts of the
world. Though different approaches are used, the ELISA
assay has been actively studied in terms of examination,
variation, and diagnosis research of FMD. A preliminary
study of ELISA was aimed at typing FMDV different
serotype, and subsequent was used to identify antigen
epitopes and evaluate the relationship or the variant
degree between reference virus and isolated strains or
circulating strains. Currently, ELISA was designed to
exploit their potential in differentiating infected from
vaccinated animals or carriers and quantitation virions
during different stages of vaccine production, particu-
larly in manufacture of pre-production, in-process and
final products test. Although theoretically the detection
of antibody to NSP’s must indicate infection rather than
vaccination, but in practice, antibody against NSPs also
might be provoked by trace amounts of NSP’s existed in
commercial vaccines and multiple vaccinations. There-
fore, currently no test has been fully validated. Whereas,
a popular viewpoint from international NSP test valida-
tion at Brescia is that the usage of multi-NSP test will
acquire the most suitable combination of tests and
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innovation and exploit related to ELISA formats was
developed as well. Starting with indirect ELISA, the
liquid-phase blocking ELISA (LPBE)[61,28] and the
solid-phase competitive ELISA(SPCE) [17,95-97] were
advocated. Other trap and competitive ELISAs detecting
animal antibody from different species have shown bet-
ter diagnostic performance. These ELISAs either use
purified antigens absorbed directly to microplates or use
polyclonal or monoclonal antibodies to trap specific
antigens from semi-purified preparations [69,73,98,99].
Regardless of the target (antigens or serum), as the
core reagent of ELISA, antibody, particularly a large
number of monoclonal antibody against FMD virus dif-
ferent regions of SP and NSP was prepared [100-107].
Accordingly, MAb based ELISAs make advances and
improvement, particularly those used in antigen map-
ping. In order to eliminate cross-reactivity as soon as
possible and increase the specificity, an approach com-
bining antiserum from rabbit or guinea-pig and mono-
clonal antibody was exploited and perform well in the
examination of FMD. In addition, antibody produced
from non-animals, such as single-chain antibody, may
show a bright future as a promising ELISA reagent.
The risk of virus release is the primary consideration
for most researchers in the choice of virus antigen. To
address this limitation, recombinant proteins and pep-
tide derived from FMDV NPs and NSPs have been
developed for alternative to whole-virus and inactivated
virus antigen. However, the narrow antigenic epitopes
harboring in such antigens have generally been insuffi-
cient to either afford solid protection of natural hosts or
potent test. But empty capsids maintain continuous and
discontinuous B-cell epitopes and T-cell epitopes pre-
senting in authentic virions [108-114] and may induce
protective responses similar to those elicited by inacti-
vated virus. At present, empty capsids of FMDV of dif-
ferent serotypes have been obtained by using either
Escherichia coli or baculovir u sa sa ne x p r e s s i o ns y s t e m
[115,116], especially a recent report of the versatility of
the baculovirus expression system [117] for the produc-
tion of P12A3C precursor of FMDV. Therefore, as a
further alternative to peptide or simple recombinant
protein, empty capsids of FMDV will open new hotspot
in the field of both ELISA reagent and vaccine antigen.
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